Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center

#1020

Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).

Aim(s): To assess the efficacy of PRRT in NETs.

Materials and methods: Retrospective analysis was performed using a database in 1000 patients (age 4-85 years) with metastatic and / or progressive NETs, undergoing 1-9 cycles of PRRT at our center, using Lu-177 (n=331), Y-90 (n=170) or both (n=499). Median total administered activity was 17.5 GBq. They were followed up for up to 132 months after the 1st cycle of PRRT. Well-differentiated NETs (G1-2) accounted for 54%. Most patients (95.6%) had undergone at least one previous therapy (surgery 86.8%, medical therapy 55%, ablative therapy 14.2% and radiotherapy 3.4%).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Kulkarni H

Authors: Baum R, Kulkarni H, Zachert C, Kaemmerer D, Petrovitch A,

Keywords: PRRT,